Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Myelodysplastic/myeloproliferative diseases
Stage/Subtype:  chronic myelomonocytic leukemia
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 68 for your search:
Start Over
Lenalidomide with or without Epoetin Alfa in Treating Patients with Myelodysplastic Syndrome and Anemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: E2905, NCI-2009-01173, CDR0000634119, ECOG-E2905, NCT00843882
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Clofarabine or Fludarabine Phosphate in Combination with Idarubicin and Cytarabine in Treating Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0788, NCI-2011-00251, NCT01289457
Donor Cytokine-Induced Killer Cells in Treating Patients with Myelodysplasia or Myeloproliferative Disorders Previously Treated with Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 50 and over
Trial IDs: BMT217, NCI-2011-01493, 5136, SU-04202010-5724, NCT01392989
Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: MCC 17259, NCI-2013-00540, 12.12.0017, NCT01776723
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3), NCT01823198
AC220 With 5-Aza or Low Dose Cytarabine
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 2012-1047, NCI-2013-02274, P50CA100632, NCT01892371
Vosaroxin and Decitabine in Treating Older Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, or Chronic Myelomonocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 60 and over
Trial IDs: 2013-0099, NCI-2013-01665, NCT01893320
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ASTX727-01, NCI-2014-01304, NCT02103478
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BS FF1050101US01, NCI-2014-01590, NCT02193958
SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STML-401-0314, NCI-2015-00337, NCT02268253
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BVD-523-02, NCI-2014-02600, NCT02296242
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B1371012, NCI-2015-00462, 2014-001345-24, NCT02367456
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BSC-101-01, NCI-2015-00719, NCT02418000
Selinexor and Sorafenib Tosylate in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0975, NCI-2015-01523, NCT02530476
Donor Stem Cell Transplant and T-Cell Infusion with or without Low-Intensity Preparative Chemotherapy Using Sirolimus in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 04-C-0055, NCI-2013-01407, 040055, 351967, NCI-2013-01404, NCT00077480, NCI-04-C-0055, NCT00074490
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 55 and under
Trial IDs: MT2005-10, NCI-2010-01444, 2005LS043, UMN-2005LS043, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2056.00, NCI-2010-00237, FHCRC-2056.00, 6171, NCT00397813
Mismatched Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and under
Trial IDs: IUCRO-0184, NCI-2011-02351, NCT00593554
Start Over